Clinical Study Protocol H0P-MC-BP01  
 
Randomized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of 
Chronic Low Back Pain  
[STUDY_ID_REMOVED] 
Approval Date: 11- May -2020 
CONFIDENTIAL Protocol  number H0P -MC-BP01
1Title Page
Intervention -Specific Appendix (ISA) for LY3016859: H0P -MC-BP01
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the cli nical 
investigation of LY3016859 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially confide ntial 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Master Protocol Title: A Master Protocol for Randomized, Placebo -Controlled, Phase 2 
Clinical Trials o f Multiple Intervent ions for the Tr eatm ent of  Chronic 
Pain
Master Protocol Number: H0P-MC-CPMP
ISA Title : Rando mized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for 
the Treatment of Chronic Low Back Pain
ISA Number: H0P-MC-BP01
Amendment Number:  This i s the ori ginal  protocol .
Compound :LY3016859
Study Phase: 2
Acronym: BP01
Sponsor Name: Eli Lilly and Co mpany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Number(s)
Master Protocol IND: 144915 
Approval Date: Protocol E lectronically Signed and Approved by Lilly ondate provi ded bel ow.
Approval Date: 11-May-2020 GMT
CONFIDENTIAL Protocol  number H0P -MC-BP01
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  number H0P -MC-BP01
3Table of Contents
1. Protocol Summary ...................................................................................................... 5
1.1. Synopsis ....................................................................................................................... 5
1.2. Schema ......................................................................................................................... 7
1.3. Schedule of Act ivities (SoA) ........................................................................................ 8
2. Introduction .............................................................................................................. 12
2.1. Study  Rati onale .......................................................................................................... 12
2.2. Background ................................................................................................................ 13
2.3. Benefit/Risk Assessment ............................................................................................ 14
2.3.1. Risk Assessment ......................................................................................................... 14
2.3.2. Benefit Assessment ..................................................................................................... 16
2.3.3. Overall Benefit: Risk Conclusio n................................................................................ 16
3. Objectives and Endpoints ......................................................................................... 17
4. Study Design ............................................................................................................. 18
4.1. Overall Desig n............................................................................................................ 18
4.2. Scientific Rationale for Study  Design ......................................................................... 19
4.3. Justification for Dose .................................................................................................. 19
4.4. End of Study  Definit ion.............................................................................................. 19
5. Study Population ...................................................................................................... 20
5.1. Inclusio nCriteria........................................................................................................ 20
5.2. Exclusio n Cri teria....................................................................................................... 20
5.3. Lifest yle Considerat ions............................................................................................. 21
6. Study Intervention .................................................................................................... 22
6.1. Study  Intervent ion(s) Administered ............................................................................ 22
6.1.1. Speci al Treatm ent Consi derat ions............................................................................... 22
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 24
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 24
6.4. Study  Intervent ion Compliance ................................................................................... 24
6.5. Concomitant Therapy ................................................................................................
.24
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 25
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 25
8. Study Assessments and Procedures ......................................................................... 26
8.1. Safety Assessments .................................................................................................... 26
8.1.1. Physical Examinat ions................................................................................................ 26
8.1.2. Electrocardiograms ..................................................................................................... 26
8.1.3. Clinical Safety  Laboratory  Assessments ..................................................................... 26
8.2. Adverse Events and Serious Adverse Events .............................................................. 26
8.2.1. Infusio n Site Reacti ons ............................................................................................... 26
8.2.2. Hypersensi tivity Reacti ons and Infusio n-related Reacti ons ......................................... 26
8.2.3. Adverse Events of Special Interest .............................................................................. 27
8.3. Treatment of Overdose ............................................................................................... 27
CONFIDENTIAL Protocol  number H0P -MC-BP01
48.4. Pharmacokinet ics........................................................................................................ 27
8.5. Pharmacodynamics ..................................................................................................... 28
8.6. ................................................................................................................. 28
8.7. Immunogenicit y Assessments ..................................................................................... 28
9. Statistical Considerations ......................................................................................... 29
9.1. Statistical Hypotheses .................................................................................................29
9.2. Sample Si ze Determinat ion......................................................................................... 29
9.3. Popul ations for Analyses ............................................................................................ 29
9.4. Statistical Analyses ..................................................................................................... 29
9.4.1. G eneral considerat ions................................................................................................ 29
9.4.2. Other Analyse(s) ......................................................................................................... 30
9.5. Interim Analyses ......................................................................................................... 30
10. Supporting Documentation and Operational Considerations ................................ 31
10.1. Appendix 1: Clinical Laboratory  Tests ........................................................................ 31
10.2. Appendix 2: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 32
10.3. Appendix 3: Recommended Laboratory  Test ing for 
Hypersensi tivity Events .............................................................................................. 35
10.4. Appendix 9: Abbreviat ions......................................................................................... 36
11. References ................................................................................................................. 38
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
51. Protocol Summary
1.1. Synopsis
Protocol Title:
Randomized, placebo -controlled, Phase 2 clinical trial to evaluate LY3016859 for the treatment 
of chronic low back pain
Rationale :
The purpose of this study  is to test whether LY3016859 is efficacious in relieving chronic low 
back pain (CLBP) .  LY3016859 i s a high affini ty hum anized immunoglobulin G ( IgG)4
monoclonal antibody  that binds to key  residues in the C -terminal regions of transforming growth 
factor -α(TGF -α) and epiregulin, prevent ing their binding to the e pidermal growth factor receptor
(EGFR).  
Data will be collected to assess the safet y and tol erabili ty of LY3016859 in this study  popul ation. 
Pharmacokinet ic properti es, pharm acodynamic effects ,and immunogenicit y profile will also be 
explored .  
The totalit y of data from  this proof -of-concept stu dywill assess the benefit s and risks
associ ated wi thLY3016859 and inform  decisio ns for the clinical development of LY3016859 .
Objectives and Endpoint s
The primary  and secondary  object ives and endpo ints are stated in the Master Protocol H0P -MC-
CPMP (CPMP) and CLBP disease -state addendum (DSA )H0P-MC-CPMP (2) (CPMP [2]). 
Overall Design
This is a 26-week, Phase 2 ,randomized, double -blind, pl acebo -controlled study that will 
compare LY3016859 versus placebo in participants with CLBP .
Disclosure Statement : This is a rando mized, investigator -and participant -blind, placebo -
controlled, Phase 2 clinical trial .
Number of Participant s:
Approximately  
150participants will be rando mly assigned to study  interventi on
(100 LY3016859 and 50placebo) with the assumption that 15% of the participants will drop out 
prior to the end of the double -blind treatment period.
Intervention Groups and Duration :
This 26 -week study  includes an 8- week double -blind treatment period and an 18 -week follow-up 
period.
Parti cipants will receive an intravenous infusio nevery  2 weeks for a total  of 4 infusi ons.
CONFIDENTIAL Protocol  number H0P -MC-BP01
6Intervention Name LY3016859 Placebo
Dosage Level(s) 750 mg starting dose
500 mg subsequent dosesNot applicable
Route of Administration
and duration1-hour IVinfusion 1-hour IV infusion
Abbreviation: IV = intravenous .
Parti cipants will be m onitored f or at l east 4 hours after complet ion of each infusio n.
Data Monitoring Committee: Yes
CONFIDE NTIAL Protocol  number H0P -MC-BP01
71.2. Schema
* Medication washout and PDEP begins.
** Randomization to either LY3016859 or placebo.  
ǂEach participant receives a 1 -hour infusion at Visits 3, 4, 5, and 6.
Abbreviations:  IV = intravenous; PDEP =preliminary data entry period; V =visit.
Washout
& PDEPUp to -6 
months
V1 V3**Week 2
V4Week 4
V5Week 6
V6Week 8
V7-10 days to V3
V2*
Screening
PeriodRandomization 
Double -Blind
Period
Placebo IV infusionǂLY3016859 IV infusionǂWeek 26
V803
Follow-upWeek 12
V801Week 16
V802
CONFIDENTIAL Protocol  number H0P -MC-BP01
81.3. Schedule of Activities (SoA)
This SoA shows visits and procedures unique to the intervent ion-specific appendix (ISA) H0P -
MC-BP01 (BP01) for LY3016859.  Please refer to M aster Protocol H0P-MC-CPMP (CPMP) 
and the CLBP disease -state addendum  (DSA) H0P -MC-CPMP( 2) SoAs for addit ional 
inform ation.  
CONFIDENTIAL Protocol  number H0P -MC-BP01
9H0P-MC-BP01 ISA
Randomization Double -Blind Treatment Follow -up Early
DiscontinuationNotes
Visit Number V3 V4 V5 V6 V7 V801 V802 V803 ED
Study Week 0 2 4 6 8 12 16 26
Visit Window 
(days)±3 ±3 ±3 ±3 ±5 ±7 ±7 Minimal interval between 2 doses cannot be 
shorter than 11 days.
Physical 
examinationX X X X X X X X X Targeted exam for skin, eyes, mouth, lungs ,and 
GI tract should be performed at each visit, in 
addition to any symptom -driven exam.  Full 
physical exam should be performed at Visit 803 
or ED.
Weight X
Vital signs X X X X X X X X Includes respiratory rate, blood pressure, 
temperature ,and pulse rate.  All vital signs are 
collected before study intervention infusion on 
V3-V6.
ECG X X X Single safety ECGs
Study  
intervention IV 
infusionX X X X 1-hour IV administration
The timing between randomization and the first 
IV infusion may be up to, but not longer than ,
2business days to reduce participant burden.
Adverse events X X X
Concomitant 
medicationX X X
Rescue 
medication 
usage reportingX If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP 
SoA.
NRS X If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP 
SoA.
PGI X If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP 
SoA.
CONFIDENTIAL Protocol  number H0P -MC-BP01
10H0P-MC-BP01 ISA
Randomization Double -Blind Treatment Follow -up Early
DiscontinuationNotes
Visit Number V3 V4 V5 V6 V7 V801 V802 V803 ED
Study Week 0 2 4 6 8 12 16 26
Visit Window 
(days)±3 ±3 ±3 ±3 ±5 ±7 ±7 Minimal interval between 2 doses cannot be 
shorter than 11 days.
RMDQ X If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP 
SoA.
C-SSRS X X Use C-SSRS Since Last Visit version.  
Self-Harm 
Supplement 
FormX X
Self-Harm 
Follow -up FormX XRequired if triggered by the Self -Harm 
Supplement Form per instructions.
Hematology X X X
Chemistry X X X X X
Urine 
ChemistriesX X X X X X X X
Urinalysis X
Urine pregnancy
X X X X X X XFor all premenopausal females or 
postmenopausal females <50 years of age
V3: collect sample before dosing .
Urine drug 
screenX X X
Hemogl obin 
A1cX X X X
CONFIDENTIAL Protocol  number H0P -MC-BP01
11H0P-MC-BP01 ISA
Randomization Double -Blind Treatment Follow -up Early
DiscontinuationNotes
Visit Number V3 V4 V5 V6 V7 V801 V802 V803 ED
Study Week 0 2 4 6 8 12 16 26
Visit Window 
(days)±3 ±3 ±3 ±3 ±5 ±7 ±7 Minimal interval between 2 doses cannot be 
shorter than 11 days.
PK sample X X X X X X X X XV3-V6:  collect samples before IV infusion 
starts and within 15 minutes after IV infusion is 
complete.
V7-V803: single sample collected at any time.
Obtain PK samples from opposite arm used for 
IV infusion.  
Record date and time of collection.
Immunogenicity 
(ADA) sampleX X X X X X XV3-V6:  collect sample before IV infusion starts .
Epiregulin 
sample X X X X X X X XV3-V6:  collect sample before IV infusion starts.
V7-V803: single sample collected at any time to 
match PK.
Abbreviations:  ADA = anti -drug antibody; C -SSRS = Columbia -Suicide Severity Rating Scale; ECG = electrocardiogram; ED = early discontinuation; GI = gastrointestinal; 
ISA =intervention -specific appendix; IV = intravenous; NRS = Numeric Rating Scale for pain; PGI = Patient Global Impression of Change; PK = pharmacokinetic; 
RMDQ =Roland -Morris Disability Questionnaire ; SoA = schedule of activities; V = visit.
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
122. Introduction
This intervent ion-specific appendix ( ISA)H0P-MC-BP01 (BP01) is an appendix to the H0P-
MC-CPMP (CPMP ) Master Protocol and contains unique study  elements specific for 
LY3016859 .  The master protocol contains the overarching study elements that govern the 
chronic low back pain ( CLBP)disease -state appendix ( DSA )H0P-MC-CPMP(2) ( CPMP [2])and 
this ISA BP01.  
LY3016859 is a high affinit y humanized immunoglo bulin G (IgG)4 m onocl onal ant ibody  that 
binds to key  residues in the C -terminal regio ns of transforming growth factor -
α(TGF -α) and 
epiregulin, preventing their binding to the e pidermal growth factor receptor (EGFR).  
Engagement of LY3016859 results in internalizat ion of the membrane -spanning ligands and 
neutralizat ion of mature ligand activit y in vitro .  
The EGFR and epiregulin are associ ated wi th pain processing (Martin et al. 2017).  Epiregulin is 
increased in blood after nerve injury/insult (Martin et al. 2017).  Inhibit ion of EGFR with 
clinically available compounds strongly re
duces nocifensive behavior in mouse models of 
inflammatory  and chronic pain, including spinal nerve injury  and chronic constriction injury
(Martin et al. 2017) .
Non-controlled reports show that EGFR inhibit ion by various oncol ogic drugs provi des rapi d 
relief of pain ( Kersten et at. 2013; Kersten et al. 2015; Juhasz et al. 2013) ,and the pain relief was 
independent of disease progression (Kersten and Cameron 2012).  
2.1. Study Rationale
The purpose of this study  is to test whether LY3016859 is efficacious in relieving CLBP .  Data
will be collected to assess the safet y and tol erabili ty of LY3016859 in this study  popul ation. 
Pharmacokinet ic (PK)properti es, pharmacodynamic (PD) effects ,and immunogenicit y profile 
will also be explored .  The totalit y of data fro m this proof -of-concept study will assess the
benefit s and risksassociated with LY3016859 and inform  decisio ns for the clinical development 
of LY3016859.
CONFIDENTIAL Protocol  number H0P -MC-BP01
132.2. Background
LY3016859 was initially devel oped f or the treatment of diabet ic nephropathy (DN) and 
2clinical studies were completed. 
Study I5V-MC -TGAA (TGAA)
Population Healthy  participants
Study Design Placebo -controlled, randomized, single -dose escalation
LY3016859 
DoseIntravenous (IV) infusion and subcutaneous:  0.1, 1, 10, 50, 250, and 750 mg
Objectives Evaluate safety, tolerability, and pharmacokinetics after single IV and subcutaneous 
dosing.
Study I5V-MC -TGAB (TGAB)
Population Participants with diabetic nephropathy 
Study Design 2-part, placebo - controlled, randomized, multiple dose escalation and parallel dose study
LY3016859 
DosePart A: dose range of 10 to 750 mg ,administered as a 60 -minute IV infusion once ever y 
3weeks for a total of 2 doses
Part B: 60-minute IV infusion once every 3 weeks up to 5 doses, if tolerated
Doses did not exceed the maximum tolerated dose from Part A .
Objectives Evaluate safety, tolerability ,pharmacokinetics ,and pharmacodynamics.
Change f rombaseline in proteinuria at 16 weeks.
Pharmacokinetics 
LY3016859 serum concentration increased more than proportionally  with dose ,and the terminal 
half-life increased wit h dose (approaching 18 days at higher doses), consistent with 
target -mediated drug disposit ion.  
Pharmacodynamics
LY3016859 demonstrated dose -related target engagement for both TGF -α and epiregulin.
Safety
Intravenous doses of up to 750 mg LY3016859 were safe and reasonably well -tolerated.
Adetailed description o f the che mistry , pharmaco logy, efficacy , and safet y of LY3016859 is 
provi ded in the Invest igator’s Brochure (IB).
CONFIDENTIAL Protocol  number H0P -MC-BP01
142.3. Benefit/Risk Assessment
The IB provides d etailed informat ion about the known and expected benefit s and risks and 
reasonably  expected adverse events (AEs) of LY3016859.
2.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention LY3016859
Development TE ADA . Incidence of TE ADA was 50% after 
a single dose, and up to 57% after 
multiple doses.Collect samples up to 20 weeks after 
last dose to characterize ADA 
profile . 
IVinfusion may be associated with 
infusion reactions and 
hypersensitivity reactions . LY3016859 is a monoclonal 
antibody that will be administered 
via IV infusion .  Hypersensitivity 
reactions and infusion reactions may 
occur during treatment with such 
agents.Monitor infusion reactions and 
hypersensitivity reactions .
Guidance on management of 
infusion andhypersensitivity 
reactions are in Sections 8.2.1 and 
8.2.2.
Dermatological adverse reactions 
similar to EGFR antagonists .One healthy  participant who 
received a single dose of 1 mg 
LY3016859 experienced a rash that 
was considered similar to those 
associated with EGFR antagonists .Collect dermatological AEs .
Stop dosing for severe 
dermatological AEs .
Changes in eGFR in pa rticipan ts 
with CLBP .A modest and non -statis tically 
significant decrease in eGFR was 
observed in pa rticipa nts with DN 
who receive dLY3016859 in Part B 
of Study TGAB, but not in healthy 
participants in Study TGAA .Exclude pa rticipants with moderate 
or severe renal impairment in the 
study.
Short dosing duration.
Monitor eGFR and stop dosing if 
necessary.
 
Fetal harm due to in utero exposure No effects on embryo -fetal 
development in enhanced pilot 
embryo -fetal development studies in 
rats and rabbits.  Definitive 
developmental and reproductive 
toxicity studies are not y et 
completed.Do not enroll women who are 
pregnant or breastfeeding in studies 
for LY3016859.
Study Procedures
Participa nt may  experience 
increased CLBP symptoms.Medications that relieve CLBP pain 
will not be allowed until Visit 801 .Rescue medication is permitted .
Standard treatment of CLBP may be 
restarted after Visit 801 based on 
investigator discretion.
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
15Abbreviations:  ADA = anti -drug antibodies; AE = adverse event; CLBP = chro nic low back pain; DN = diabetic 
nephropathy ; EGFR = epidermal growth factor receptor; eGFR = estimated glomerular filtration rate; 
IV=intravenous; TE = treatment emergent; TGAA = Study I5V-MC -TGAA; TGAB = Study I5V -MC -TGAB.
CONFIDENTIAL Protocol  number H0P -MC-BP01
162.3.2. Benefit Assessment
Potenti al benefi ts for the study  parti cipants include 
study -related medical procedures 
ophysical examinat ions 
olaboratory  tests 
oelectrocardi ogram s (ECGs) 
As part of Study  CPMP, parti cipants to thi s ISA will  report thei r experi ence using standard tools 
that will contribute to the assessment of novel treatments for CLBP.  In addit ion, data collected 
from this study  may also improve our understanding of pathogenesis.  Both of which may  lead to 
the development of a new treatment with improved safet y and efficacy  profile com pared to 
standard of care.
2.3.3. Overall Benefit: R isk Conclusion
The m easures taken to minimize risk to participants in this study  and the potenti al risks i dentified 
in associat ion with ISA BP01 are j ustified by  the ant icipated benefits to participants with CLBP.
CONFIDENTIAL Protocol  number H0P -MC-BP01
173. Objectives and Endpoints
The CPMP Master Protocol and CLBP DSA CPMP( 2) include obj ectives and endpo ints 
applicable for this study .  Thi s table describes objectives and endpo ints specific for LY3016859.
Objectives Endpoints
Tertiary/Exploratory
Characterize the PKand PDof LY3016859 af ter 
multiple IVinfusions in participants with CLBPAssessment of serum concentrations of LY3016859 
and epiregulin to enable PKand PDevaluations
Characterize immunogenicity of LY3016859 Appearance of anti -drug antibodies and neutralizing 
antibodies to LY3016859
Explo re the effect of LY3016859 on the kidney Assessment of 
urine albumin/creatinine ratio
urine protein/creatinine ratio
eGFR
Abbreviations:  CLBP = chronic low back pain; eGFR = estimated glomerular filtration rate ; IV = intravenous; PD = 
pharmacodynamics ;PK=pharmacokinetics .
CONFIDENTIAL Protocol  number H0P -MC-BP01
184. Study Design
4.1. Overall Design
The CPMP Master Protocol and CLBP CPMP(2) DSA describes the overall study  design and 
study  design rati onale.  This sect ion describes visit s and overall procedures unique to ISA BP01 
for LY3016859 in addit ion to the procedures outlined in theCPMP Master Protocol and 
CPMP(2) DSA .  
Double -blind Treatment Period (Visits 3 through 7)
Each visit is an outpatient visit.
At Visit 3
participants are randomized to LY3016859 or placebo  
the site com pletes the BP01 baseline procedures and sample co llection 
participants receive their first dose of study  intervent ion via intravenous ( IV)infusio n 
over 1 hour 
the site observes part icipants in the clinic for at least 4 hours after the comple tion of  the 
IV infusio n 
the site com pletes all post- treatm ent sam ple collectio n and safety  monitoring, and
the site instructs participants to continue with study  restri ctions and Numeric Rat ing 
Scale (NRS) di ary entri es before thei r visit discharge.
At Visits 4 through 6  
the site revi ews available safet y data and com pletes pre -dose procedures and sample 
collect ion
participants receive an IV infusio n over 1 hour 
the site observes part icipants in the clinic for at least 4 hours after the completion o f the
IV infusio n
the site com pletes all post- treatm ent sam ple collectio n and safety  monitoring, and
the site instructs participants to continue with study  restri ctions and NRS diary  entries 
before their visit discharge. 
At Visit 7
the site com pletes all proce dures and sample co llection noted in the schedule of activit y 
(SoA)s
no intervent ion is administered at this visit, and 
the site instructs participants to continue with study  restri ctions and NRS diary  entries 
before their visit discharge. 
Post-treatment Follow -up Period (Visits 801- 803) 
Parti cipants must com plete 3 post -treatm ent follow-up vi sits for safet y, PK, epiregulin PD,and 
immunogenicit y assessment at Visits 801 through 803, according to the SoA.
CONFIDENTIAL Protocol  number H0P -MC-BP01
19The site schedules Visit 801 approximately 4 we eks after Vi sit 7. 
At Visit 801, participants return the device for NRS diary co llection. 
At Visit 803, the participants are discharged from the study . 
If the participant receives at least one dose of intervent ion and di scontinues during the double-
blind treatm ent peri od, they  shoul d com plete early di scontinuat ion procedures per the CPMP 
Master P rotocol SoA ,and Visit 801 should be scheduled approximately 30 days after the last 
dose of study  intervent ion.
4.2. Scientific Rationale for Study Design
The CPMP Master Protocol describes the overall study design rationale.
Efficacy data will be collected up to 6 weeks after the last dose, based on the long PK half -life 
and potenti al sustained target engagement of LY3016859.
Safety, PK, PD,and immunogenicit y sampl es will  be collected up to 20 weeks after the last 
administration of intervent ion to characterize the safet y and clinical immunogenicit y profile. 
4.3. Justification for Dose
The proposed dose for proof -of-concept i s a 750 -mg starting dose fo llowed by 500 mg ev ery 
2weeks IV for a total of 4 doses.  The dose level and duration are based on the available 
toxicology, safet y, PK,and PDdata from  the com pleted studi es detailed in the LY3016859 IB. 
Briefly, the proposed dose regimen maintains an approximate 10 -foldmargin o f safety  (MOS) 
relative to the no-observed -adverse -effect l evel (NOAEL) for both rat and monkey  repeated dose 
toxicology studi es (located in the IB) and i s expected to achieve steady  state exposure similar to 
the 750 mg every 3 weeks dosing regimen tested in Study TGAB.  The safet y data from  the 
completed TGAA and TGAB studies and the clinical management plan support testing the 
proposed dose regimen in participants with various chronic pain condit ions. 
The PK analyses show a similar PK profile for LY3016859 in healt hy participants and pat ients 
with various degrees of renal impairment, which is expected for a monoclonal ant ibody .  
While the degree o f target engagement required for analgesic efficacy for LY3016859 has not 
been established in the clinic, the proposed dosing regimen is expected to reach steady -state 
within a m onth
.  If the epiregulin blockade is beneficial for CLBP , then this level o f target engagement 
is expected to enable analgesic efficacy .  
4.4. End of Study Definition
A participant is considered to have co mpleted th isISA if heor she has completed all required 
phases of the study  including the last scheduled procedure shown in the ISA SoA.
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the ISA SoA for the l ast parti cipant.
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
205. Study Population
The CPMP Master Protocol and CLBP CPMP(2) DSA provide eligibilit y criteria that m ust be 
followed for thi s study .  LY3016859 -specific inclusion and exclusio n criteria are listed here.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
[2000] are men or women who abide by the reproductive and contraceptive requirements 
provi ded in BP01 Section 10.2, Appendix 2
[2001] arewilling to discontinue all pain medicat ions for condit ion under study  except 
rescue m edicati on permitted per protocol until V801 in the fo llow-up peri od
[2002] must have venous access in both arms f or IV infusion and sample collection.  
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
[2003] Have an estimated glomerular filtration rate (eGFR )of less than 70 ml/min/1.73m2
based on the Chronic Kidney Disease Epidemio logy Collaborati on(CKD -EPI)
formula at Visi t1 or Vi sit 2
[
2004] Have any clinically  serious or unstable cardiovascular, musculo skeletal  disorder, 
gastrointestinal (GI), endocrino logic, hematol ogic, hepat ic, metabolic, urologic, 
pulmo nary, derm atologic, immunol ogic, or ophthalmo logic disease within 3 mo nths 
of Visi t 3
Prior/Concomitant Therapy
[
2005] have received any  antibodi es against nerve growth factor (NGF), antibodies against 
EGFR, or EGFR ty rosine kinas e inhibi tors(TKI) .
[
2006] have a history  of allergic reactions to monoclonal ant ibodies, or clinically 
significant m ultiple or severe drug allergies, including but not limited to ery thema 
multiforme major, linear immunogl obulin A dermatosis, toxic epiderm al necrolysis, 
or exfo liative dermat it
is
[2007]have a history  or presence of uncontrolled asthma, eczema, significant atopy , 
significant heredi tary angi o-edema ,or commo n vari able immune deficiency , and
Reproductive
[2008] wom en who are pregnant or breast feeding.
CONFIDENTIAL Protocol  number H0P -MC-BP01
215.3. Lifestyle Considerations
Reproductive and Contraception Requirements
Reproductive requirements and contraceptive guidance are provided in BP01 Appendix 2, 
Secti on10.2.  
Caffeine and Alcohol
Parti cipants shoul d maintain thei r usual  caffeine intake.  
Parti cipants shoul d limi t thei r alcohol  consumpti on for the durati on of  the study .  
Men up to the age of 6 5 shoul d not exceed an average weekly alcoho l intake of21 units per 
week .  
Men over the age of 65 and women should not exceed an average weekly alco hol intake of
14units per week.
One unit of alcoho l equals
12 oz or 360 mL of beer 
5 oz or 150 mL of win e, or
1.5 oz or 45 mL of distilled spirits .
Activities
Parti cipants are requi red to maintain similar levels of activit y during the double -blind study  
period.  Starting a new exercise program or new strenuous activit y is not allowed.  
Parti cipants who rec eive physical therapy for CLBP should remain on the same therapy program 
(intensit y and frequency) from Visit 3 to Visit 801.  New programs may be init iated after 
Visit 801.
Exposure to Sun
Parti cipants shoul d use sun protection and avoid sunbathing and use of sun beds for the duration 
of the study .  Sun protecti on m ay consist of protective clothing or sun protection factor ( SPF) 50 
lotion.
CONFIDENTIAL Protocol  number H0P -MC-BP01
226. Study Intervention
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or m edical device(s) intended to be administered to a study  parti cipant according to the 
study  protocol .
6.1. Study Intervention(s) Administered
The study  intervent ion will be administered via a slow IV infusio n over approximately 1 hour by  
blinded site personnel.  The infusio n rate m ay be reduced as deemed necessary  if an infusi on 
reacti on is observed (see Section 6.1.1.2 ).  Parti cipants will be mo nitored for at least 4 hours 
after com pletion of each infusio n.  Site must have resuscitat ion equipment, emergency drugs ,and 
appropriately training staff available during the infusion and for at least 4 hours after the 
completion of the infusio n.  Parti cipants shoul d not use tobacco products from 1 hour before the
start of dosing until after collect ion of the final PK or PDsampleafter dosing .  
Intervention Name LY3016859 Placebo
Type Biologic Not applicable
Dose Formulation Lyophilized powder 0.9% Sodium chloride solution
Unit Dose Strength(s) 75 mg/vial Not applicable
Dosage Level(s) 750 mg starting dose
500 mg subsequent dosesNot applicable
Route of Administration 1-hour IV infusion 1-hour IV infusion
Use experimental placebo
IMP and NIMP IMP NIMP
Abbreviations:  IMP = investigational medicinal product; IV = intravenous; NIMP = non -investigational medicinal 
product.
6.1.1. Special Treatment Considerations
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned.  However, if an infusion react ion occurs, the study  
investigator(s ) should determine the appropri ate premedication for subsequent infusio ns for that 
participant .
The invest igator sand sponsor may decide to usepremedicat ion for all participants.  They  will 
decide this if the frequency of infusio n reactions amo ng participants warrants it .
Any premedicat ions given will be documented as a concomitant therapy  (see Secti on6.5).
CONFIDENTIAL Protocol  number H0P -MC-BP01
236.1.1.2. Management of Infusion Reactions
All participants shoul d be m onitored cl osely , asthere is a risk of infusio n reaction and 
hypersensit ivity (incl uding anaphylaxis) with any bi ological  agent.   
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to ,
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash, 
pruri tus, myalgia, and dizziness.  
Site Needs
The clinical site should have necessary equipment and medicat ions for the m anagement of any 
infusio n reaction, which may include but is not limited to oxy gen, IV fluid, epinephrine, 
acetaminophen ,and ant ihistamine.
Management of Infusion Reaction s
Invest igators should grade the severit y of the infusio n reaction andmanage infusio n react ions 
based on standard of care and their clinical  judgment .  If an infusio n reaction occurs, then 
supportive care should be used in accordance with the signs and sy mptom s.
This table outlines guidance when a mild to moderate infusio n reaction occurs.
If… Then…
a mild to moderate infusion reaction occurs the infusion rate should be slowed or stopped depending 
on the symptoms or signs present.
For example, reducing the rate by 50% from 
2 mL/minute to 1 mL/minute.
the infusion rate is slowed the infusion should be completed at the slower rate, 
as tolerated.
subsequent infusions may be administered at the 
discretio n of the investigator in agreement with the 
Lilly  medical monitor. 
the infusion rate is slowed, and subsequent infusions are 
continuedthe infusion rate must be maintained at the slowest 
tolerated rate used. 
The s tudy intervent ion infusio n shoul d be stopped immediately  and perm anent ly if it is an 
infusio n reaction
with systemic invo lvement, including, but not limited to ,significant treatm ent-emergent
(TE) hypotension, bronchospasm, or wide -spread urticaria 
that does not respond to a slower infusion rate or oral medications
that is determined as clinically  significant by  the investi gator.  
If a participant permanent ly discontinues fro m study  intervent ion, they  shoul dcomplete AE
monitoring and ot her procedures as stated in Section 4, Study  Design, and the CPMP Master 
Protocol ,CPMP(2) DSA, and BP01 SoAs.
CONFIDENTIAL Protocol  number H0P -MC-BP01
246.2. Preparation/Handling/Storage/Accountability
Study  intervent ion and placebo will be prepared and verified by unblinded site personnel .
6.3. Measures to Minimize Bias: Randomization and Blinding
No addi tional stratificat ion factors are considered for this ISA.  
6.4. Study Intervention Compliance
Participants will receive study  intervent ion directly fro m the invest igator or designee , under 
medical supervisio n.  The date and time of each study  intervent ionadministered in the clinic will 
be recorded in the source documents and case report form ( CRF ).  Ad ministration of intervent ion
and study  parti cipant i dentification will be confirme d at the time of dosing by a member of the 
study  site staff other than the person administering the study  interventi on.  
6.5. Concomitant Therapy
All conco mitant therapi es that are part of routine care for other comorbidit ies besides CLBP , are 
allowed and can be used during the study , if it is permitted based on the inclusio n and exclusio n 
criteria.  
A list of medications that are prohibited fro m Visit 2 to Visi t 801 f or parti cipants randomized to 
this ISA study  will be provi ded.  Parti cipants m ay return to th eir standard ofcare after Visit 801 
is co mpleted, as clinically appropriate.
CONFIDENTIAL Protocol  number H0P -MC-BP01
257. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
The CPMP Master Protocol and CPMP(2) DSA provides the reasons and procedures for 
discontinuat ion of intervention and participant discontinuat ion that m ust be fo llowed for thi s 
study .  LY3016859 specific informat ion is included here.
7.1. Discontinuation of Study Intervention
If the invest igator, afte r consul tation wi th the sponsor -designated medical mo nitor, determines 
that a sy stemic hypersensit ivity reacti on or a seri ous infusi on reacti on has occurred rel ated to 
study  interventi on administrati on, the parti cipant shoul d be perm anent ly discont inued fr om the 
study  interventi on. 
A participant should be discont inued fro m study  intervent ion if they experience a dermatological 
adverse reaction, such as acneiform rash, that is related to study  intervent ion, and is either mild 
to moderate and does not respon d to topi cal treatm ent or is severe.  The participant may cont inue 
in the study  at the di scret ion of the invest igator in consultation wit h the m edical m onitor or study  
sponsor phy sician/scient ist.
CONFIDENTIAL Protocol  number H0P -MC-BP01
268. Study Assessments and Procedures
Study  procedures and their timing are summarized in the CPMP Master Protocol , CLBP 
CPMP(2) DSA, and ISA BP01 SoAs.  
LY3016859 -specific assessments and procedures are described here.
8.1. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoAs. 
8.1.1. Physical Examinations
Targeted physical examinat ions of skin, eyes, mo uth, lungs , and GItract will be performed at 
each visit as described in the SoA.  Any clinically significant abnormal physical examinat ion 
findings will be reported as AEs. 
8.1.2. Electrocard iograms
Single 12 -lead ECG will be obtained as outlined in the SoA using an ECG machine that 
autom atically calculates the heart rate and measures pulse rate, QRS, QT, and corrected QT 
interval  (QTc). 
8.1.3. Clinical Safety Laboratory Assessments
See BP01 Appendix 1 (Section 10.1) for the list of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequency for ISA BP01. 
8.2. Advers e Events and Serious Adverse Events
8.2.1. Infusion Site Reactions
Symptom s of a l ocal infusi on site reacti on may  include ery thema, indurat ion, pain, pruritus, and 
edem a.If an infusio n site event is reported, the AE will be recorded, and additional data will be
provi ded to the sponsor in the CRF.
Addit ional blood and urine samples should be co llected as described in BP01 Section 10.3, 
Appendix 3, “Recommended Laboratory  Test ing for Hy persensi tivity Events”.   Laboratory 
resul ts are provi ded to the sponsor vi a the central  laboratory .
8.2.2. Hypersensitivity Reactions and Infusion -related Reactions
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity 
reacti ons.  Drugs administered via IV infusio n may lead to a sy stemic infusio n-related reacti on.  
If such a react ion occurs, additional data describ ing each symptom should be provided to the 
sponsor in the CRF.  
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving study  intervent ion.  It i s recommended that 
participant s who experience a systemic reaction be treated per the local standard of care.  
CONFIDENTIAL Protocol  number H0P -MC-BP01
27In the case of generalized urticaria or anaphylaxis, or moderate to severe infusio n-related 
reacti ons, addi tional bl ood and urine samples should be collected as described in BP01 
Secti on10.3, Appendix 3, “Reco mmended Laboratory  Testing for Hy persensi tivity Events .”  
Laboratory  resul ts are provi ded to the sponsor via th e central  laboratory .
8.2.3. Adverse Events of Special Interest 
Dermatological adverse reactions
EGFR ant ibodies or EGFR -associ ated TKI are associated with various dermatological AEs, 
including acneiform rashes, xerosis, prurit is, and photosensit ivity.  Secondar y infect ion can also 
develop. 
Parti cipants shoul d use sun protection during the study  period.  Derm atological  adverse reacti ons 
shoul d be managed by the invest igator according to standard of care.  Discont inuat ion of 
treatm ent m ay be considered if these A Es do not respond to topical treatment, are widespread 
(>30% body  surface area) ,or are severe.
If any o f these AEs are reported, sites will be prompted to provide addit ional informat ion. 
Renal Function
Changes in eGFR were observed in part icipants with DNin Study TGAB (Section 2.2).  Such 
changes were reversible and were not associated wit h an increase in proteinuria.  Blood and urine 
samples will b e collected to characterize the effects of LY3016859 on renal funct ion,and eGFR 
will be mo nitored duri ng the study . 
8.3. Treatment of Overdose
In case of suspected overdose, participants should be mo nitored for any  signs or symptom s of 
adverse reactions or effects, and supportive care should be provided as necessary. 
8.4. Pharmacokinetics
Venous blood samples will  be collected for m easurem ent of  LY3016859 concentrations as 
specified in the SoA.   Samples will be used to evaluate the PK of LY3016859 .  
A maximum o f 3samples may be collected at additional t ime po ints during the study  if 
warranted and agreed upon between the invest igator and the sponsor.  
Instructi ons for the collect ion and handling of bio logical samples will be provided by Lilly. 
Site personnel w ill record
The date and time (24 -hour clock time) of LY3016859 administration (start and end of 
infusio n), and
The date and time (24 -hour clock time) of each PK sample.
It is essent ial that the times are recorded accurately.
Pharmacokinet icsamples will be retained for a m aximum  of 2 years fo llowing last subject visit 
for the study .
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
288.5. Pharmacodynamics
Venous blood samples will be collected for the measurement of epiregulin as specified in the 
SoA.  Any remaining blood samples may be used to test other potential PDendpo ints, including, 
but not limited to TGF -α. 
Instructi ons for the col lection and handling of bio logical samples will be provided by Lilly.
8.7. Immunogenicity Assessments
Visits and times
At the visit s and t imes specified in the SoA, predose venous blood samples will be collected to 
determine antibody  producti on against LY3016859.  The actual date and time (24 -hour clock 
time) of each sam ple collection will be recorded.
If the immunogenicit y sample at the last scheduled assessment or discont inuat ion visit is TE 
anti-drug ant ibody  (ADA) positive (as defined in Secti on 9.4.2.1 ), addi tional samples may  be 
taken unt il the signal returns to baseline (i.e., no longer TE -ADA posit ive) or for up to 1 y ear 
after last dose.
To ai d interpretati on of  these results, a predose blood sample for PK analysis will be collected at 
the sam e time points. 
Sample collection, handling, and use
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.
Immunogenicit y will be assessed by  a validated assay  designed to detect ADAs in the presence 
of LY3016859 at a laboratory approved by  the sponsor.  Antibodies may  be further characteri zed 
for thei r abili ty to neutralize the activit y of LY3016859.  
Sample retention
Sample retenti on is described in CPMP Master Protocol , Appendix 1, Secti on 10.1.12 .
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
299. Statistical Considerations
The CPMP Master Protocol and CLBP DSA CPMP (2)provide statistical considerations.
LY3016859 -specific considerat ions are described here.
9.1. Statistical Hypotheses
The CPMP Master Protocol describes the primary  hypothesis.  
 
. 
9.2. Sample Size Determination
Approximately  150 parti cipants will be randomized in a 2:1 rati o to LY3016859 and placebo, 
respectively .  It i s expected that approximately 128participants will co mplete the double -blind 
treatment period of  the study .  
 
 
.  If there i s no treatm ent 
difference between placebo and LY3016859, the probabilit y of passing the efficacy criterion 
specified above (i.e., false posit ive) is less than 0.
05.  The simulat ion for the power calculation 
and sample size determinat ion wa
s carri ed out in FACTS Versio n 6.0.
9.3. Populations for Analyses
The populat ions are defined in the CPMP Master Protocol .
The PKpopulati on includes all randomized part icipants who received a full dose of LY3016859 
at Vi sit 3 and have at l east 1 eval uable PK sample collected prior to dosing at or after Visit 4. 
9.4. Statistical Analyses
Any change to the data analysis methods described in this ISA will require an amendment only if 
it changes a principal feature of the ISA.  Any  other change to the data analysis methods 
described, and the just ificat ion for making the change, will be described in the statist ical analysis 
plan (SAP) and th e clinical  study  report.  Addi tional expl oratory  analyses of the data will be 
conducted as deemed appropriate.
The ISA SAP will be finalized prior to unblinding, and it will include a more technical and 
detailed descript ion of the statist ical analyses desc ribed in this section.
9.4.1. General considerations
The primary  endpoint and analyses have been described in the CPMP Master Protocol. 
CCI
CCI
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
30Any borrowing of placebo or treatment effect informat ion will be specified in the ISA SAP .  
Secondary  and terti ary/expl oratory endpoints and analyses are described in the CPMP Master 
Protocol  and CLBP DSA CPMP( 2). 
9.4.2. Other Analyse (
s)
9.4.2.1. Immunogenicity
Treatment -emergent ADAs are defined as participants
with a 2-fold (1 dilution) increase in t iter than the minimum required dilut ion if no ADAs 
were detected at baseline (treatment -induced ADA) or 
with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatme nt-boosted ADA).
The frequency and percentage of participants with preexist ing ADA and who are TE -ADA+ to 
LY3016859 will be tabulated .  
If neutralizing ant ibodies are assessed, the distributio n of titers and frequency  of neutralizing 
antibodies for the TE -ADA+ participant smay also be tabulated.
The rel ationship between the presence of ant ibodies and PK parameters, PDresponse, safet y, or 
efficacy  to LY3016859, may also be assessed.  Additional details may be provi ded in the SAP.
9.4.2.2. Pharmacokinetic and Pharmacodynamic Analyses
Pharmacokinet ic and pharmacokinet ic-pharmacodynamic (PK-PD)analyses may be conducted 
to explore the exposure -response relat ionships for various PDmeasures.  The analyses will be 
perform ed using population analysis software, NONMEM, if data allows.  The versio n of any  
software used for the analysis will be documented, and the program will meet the s ponsor 
requi rements of so ftware validat ion.  It i s possible that other validated, equivalent PK software 
programs may be used if appropriate, warranted, and approved by Global PK/ PDmanagement.  
Data m ay be pool ed wi th data from  other studi es for an integrated PK/ PDanalysis.  The 
observed serum concentrat ions for LY3016859 and epiregulin will be reported graphically  and 
descript ively.
A limited number of pre -identified individuals independent of the study  team  may receive access 
to unblinded data, as specified in the unblinding plan, prior to the interim o r final database lock, 
in order to init iate the final populat ion PK/ PDmodel devel opment processes.  Informat ion that 
may unblind the study  during the analyses will not be reported to study  sites or blinded study  
team  until the study  has been unblinded.
9.5. Interim Analyses 
An interim analysis may be conducted for internal decisio n making.  Unblinding details would 
be specified in the unblinding plan sect ion of the SAP or in a separate unblinding document. The 
SAP will describe any  interim analyses in greater detail should they  occur. 
CONFIDENTIAL Protocol  number H0P -MC-BP01
3110. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Clinical Laboratory Tests
The CPMP Master Protocol describes tests that may be performed at additional t imes noted in 
the SoA for this ISA.  This table describe s tests unique for ISA BP01.  
Chemistry Urine Chemistries Other Tests
Cystatin-C Albumin Immunogenicity
Creatinine Epiregulin
ACR LY3016859 
concentration
. Protein Urine pregnancy
PCR
Abbreviations: ACR = albumin/creatinine ratio; PCR = protein/creatinine ratio .
Refer to Section 10.3, Appendix 3 for recommended laboratory  testing for hy persensi tivity 
events.
CCI
CONFIDENTIAL Protocol  number H0P -MC-BP01
3210.2. Appendix 2: Contraceptive Guidance and Collection of Pregnancy 
Information
Women
Women of child
-bearing potenti al may part icipate in this study.
Women of child- bearing potenti al must test negative for pregnancy  prior to ini tiation of 
treatm ent as indicated by  a negative serum pregnancy test at the screening visit followed by  a 
negat ive urine pregnancy test within 24 hours prior to exposure.
Women of child-bearing potenti al who are com pletely  abstinent or in a same sex relat ionship, as 
part of their preferred and usual lifest yle, must agree to either remain abst inent or stay  in a same 
sex rel ationship wit hout sexual relat ionships with males.
All other women of child -bearing potential must agree to use two forms of effective 
contraception, where at least one form is highly effective (less than 1% failure rate), for the 
entirety of the study .  
Abstinence or contraception must continue for 90 days after the la st dose of intervent ion.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effec tive methods of contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
Not Acceptable Methods of Contraception
Use of male and female condoms as a double barrier method is not considered acceptable due to 
the high f ailure rate when these barrier methods are combined. 
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not an effect ive or 
acceptable method of contraception.  
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, post -ovulati on methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Women not of childbearing potential may participate and include those who 
have a congenital ano maly such as Mullerian a genesis 
are infert ile due to surgical sterilizat ion, or 
are post- menopausal.  
Surgical sterilizat ion examples include
CONFIDENTIAL Protocol  number H0P -MC-BP01
33hysterectomy 
bilateral  oophorectomy, or 
tubal  ligation.  
At least 6 weeks must have passed after surgical bilateral oophorectomy with or wi thout 
hysterectomy, or after tubal ligat ion.
Post-menopausal is defined as either
a wom an at l east 40 y ears of age with an intact uterus, not on hormone therapy , who has 
cessat ion of menses for at least 1 y ear wi thout an alternat ive medical cause , AND a 
follicle -stimulat ing horm one >40 m IU/mL
a wom an 55 or ol der not on horm one therapy , who has had at l east 12 m onths of 
spontaneous amenorrhea, or
a wom an at l east 55 y ears of age with a diagnosis of menopause prior to starting hormone 
replacement th erapy .
Men
Men, regardless of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one addit ional highly effect ive method 
of contracepti on (less than 1% failure rate) or ef fective method of contraception with non -
pregnant women of child bearing potential partners for the duration of the study and until their 
plasma concentrations are below the level that could result in a relevant potential exposure to a 
possible fetus, pred icted to be 6 months after the last dose.
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of estimated relevant potential exposure to the fetus, predicted to be 6 months 
after the l ast dose.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contracept ion comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
Men and their partners may  choose to use a double –barrier m ethod of contraception that must 
include use of a spermicide.
Other Guidance
Men should refrain fro m sperm  dona tion for the durati on of  the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potenti al exposure to a possible 
fetus , predi cted to be 6 m onths after the last dose. 
CONFIDENTIAL Protocol  number H0P -MC-BP01
34Men who are in exclusively same sex relat ionships, as their preferred and usual lifest yle, are not 
requi red to use contraception. 
CONFIDENTIAL Protocol  number H0P -MC-BP01
3510.3. Appendix 3: Recommended Laboratory Testing for Hypersensitivity 
Events 
Reco mmended laboratory tests should be performed at the tim e of a systemic hypersensit ivity 
event.  The management of the adverse event may  warrant l aboratory  testi ng bey ond that 
described below and should be performed as clinically indicated.
Laboratory  testing during a Sy stemic Hypersensit ivity Event is p erformed to
help characterize and classify systemic hypersensitivit y react ions
meet regulatory  expectati ons, and
improve subsequent clinical management by  helping to di stinguish between the various 
mechanist ic bases of anaphylaxis.
If anaphylaxis is suspected or generalized urticaria is present, then
1.
obtain a sample within 1 to 2 hours of the event.  
a.samples may  be obtained as late as 12 hours after the event as analy tes can remain 
altered for an extended period of time 
2.record the time at which the sample was collected, and
3.obtain a fo llowup sample at the next regularly scheduled visit or after 4 weeks, whichever 
is later.
Laboratory Tests for Hypersensitivity Events
Test Details
Tryptase If a try ptase sample is obtained more than 2 hours after the 
event (i.e. within 2 to 12 hours), or is not obtained because 
more than 12 hours have lapsed since the event, then obtain 
urine for NMH testing. 
For try ptase serum samples obtained within 2 to 12 hours 
of the event, urine NMH testing is performed in addit ion to 
tryptase testing. 
Collect the first void urine following the event .  Obtain a 
follow -up urine for NMH testing at the next regularly 
scheduled visit or after 4 weeks, whichever is later.
ADA ADA testing should include drug -specific IgE or the BAT. 
The BAT requires a serum sample .
LY3016859 PK concentration
Complement C3a, C5a
Cytokines IL-6, IL-1β, IL-10 (or any cytokine panel that includes 
these 3 cy tokines)
Abbreviations: ADA = anti-drug antibody; BAT = basophil activation test; IgE = i mmunoglobulin E ; 
IL-1β = i nterleukin 1 beta; IL -6 = i nterleukin 6; IL -10 = i nterleukin 10; NMH = N-methy lhistamine; 
PK=pharmacokinetic .
NOTE: All tests will be performed by a Lilly -designated central laboratory .
CONFIDENTIAL Protocol  number H0P -MC-BP01
3610.4. Appendix 9: Abbreviations
Term Definition
ADA anti-drug antibody
AE adverse event
blinding/masking A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
CKD- EPI Chro nic Kidney Disease Epidemiology Collaboration
CLBP chronic low back pain 
compliance Adherence to all study -related, good clinical practice, and applicable regulatory 
requirements.
CRF case report form
C-SSRS Columbia -Suicide Severity Rating Scale
DN diabetic nephropathy
DSA disease -state addendum
ECG electrocardiogram
eGFR estimated glomerular filtration rate
EGFR epidermal growth factor receptor
GI gastrointestinal
IB Investigator’s Brochure
IgG immunoglobulin G
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used o r 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ISA interventio n-specific appendix
IV intravenous
MOS margin of safety
NGF nerve growth factor
CONFIDENTIAL Protocol  number H0P -MC-BP01
37NOAEL no-observed -adverse -effect level
NRS Numeric Rating Scale for pain
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PD pharmacodynamic (s)
PK pharmacokinetic (s)
QTc corrected QT interval
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SoA schedule of activities
SPF sun protection factor
TE treatment -emergent
TE-ADA+ treatment -emergent anti -drug antibody positive
TGF-α transforming growth factor -α
TKI tyrosine kinase inhibitors
CONFIDENTIAL Protocol  number H0P -MC-BP01
3811. References
Juhasz E, Kim JH, Klingelschmitt G, Walzer S. Effects of erlotinib first -line maintenance 
therapy  versus placebo on the healt h-related quali ty of life of pat ients with metastati c non -
small -cell l ung cancer. Eur J Cancer . 2013;49(6):1205 -1215.
Kersten C, Ca meron MG. Cetuximab alleviates neuropathic pain despite tumour progression. 
BMJ Case Rep . 2012;2012 :bcr1220115374.
Kersten C, Cameron MG, Mjaland S. Epithelial growth factor receptor (EGFR) -inhibit ion for 
relief o f neuropathi c pain -A case series. Scand J P ain. 2013;4(1):3 -7.
Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor -inhibit ion 
(EGFR -I) in the treatment of neuropathic pain. Br J Anaesth . 2015;115(5):761 -767.
Martin LJ, Smit h SB, Khoutorsky  A, Magnussen CA, Samoshkin A, Sorge RE, Cho C, 
Yosefpour N, Sivaselvachandran S, Tohy ama S, Col e T, Khuong TM, Mir E, Gibson DG, 
Wieskopf JS, Sotocinal SG, Aust in JS, Meloto CB, Gitt JH, Gkogkas C, Sonenberg N, 
Greenspan JD, Fillingim RB, Ohrbach R, Slade GD, Knott C, Dubner R, Nackley AG, 
Ribeiro -da-Silva A, Neely GG, Maixner W, Zaykin DV, Mogil JS, Diatchenko L. Epiregulin 
and EGFR interact ions are invo lved in pain processing. J Clin Invest . 2017;127(9):3353- 3366.
Leo Document ID = 96ebf804-6a17-4538-a85c-f74fd23c8922
Approver: 
Approval Date & Time: 08-May-2020 18:23:12 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 11-May-2020 13:51:53 GMT
Signature meaning: Approved
PPD
PPD